Company Information

Location

San Francisco, USA

CEO

Julie Eastland

Website

www.harpoontx.com

At the heart of Harpoon’s approach is a novel antibody-derived platform called TriTAC™ (Tri-specific T cell Activating Construct) designed for targeted penetration and destruction of solid tumor malignancies, and engineered to bind to human serum albumin for improved therapeutic schedule and patient convenience.

Harpoon was founded in 2015 by a small team led by Patrick Baeuerle, Ph.D., a pioneer in the development of T cell based cancer therapies, and Luke Evnin, Ph.D., a founder of MPM Capital.

Latest Updates